112 related articles for article (PubMed ID: 1540190)
1. Enzymatic properties of the phosphorylated urokinase-type plasminogen activator isolated from a human carcinomatous cell line.
Takahashi K; Kwaan HC; Koh E; Tanabe M
Biochem Biophys Res Commun; 1992 Feb; 182(3):1473-81. PubMed ID: 1540190
[TBL] [Abstract][Full Text] [Related]
2. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors.
Ellis V; Wun TC; Behrendt N; Rønne E; Danø K
J Biol Chem; 1990 Jun; 265(17):9904-8. PubMed ID: 2161846
[TBL] [Abstract][Full Text] [Related]
4. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor.
Adams DS; Griffin LA; Nachajko WR; Reddy VB; Wei CM
J Biol Chem; 1991 May; 266(13):8476-82. PubMed ID: 1827121
[TBL] [Abstract][Full Text] [Related]
5. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
7. Separation and characterization of nonphosphorylated and serine-phosphorylated urokinase. Catalytic properties and sensitivity to plasminogen activator inhibitor type 1.
Franco P; Mastronicola MR; De Cesare D; Nolli ML; Wun TC; Verde P; Blasi F; Stoppelli MP
J Biol Chem; 1992 Sep; 267(27):19369-72. PubMed ID: 1527056
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Baker MS; Bleakley P; Woodrow GC; Doe WF
Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
[TBL] [Abstract][Full Text] [Related]
9. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Baker MS; Liang XM; Doe WF
Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
[TBL] [Abstract][Full Text] [Related]
10. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.
Cubellis MV; Wun TC; Blasi F
EMBO J; 1990 Apr; 9(4):1079-85. PubMed ID: 2157592
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.
Corti A; Nolli ML; Soffientini A; Cassani G
Thromb Haemost; 1986 Oct; 56(2):219-24. PubMed ID: 3101222
[TBL] [Abstract][Full Text] [Related]
12. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
13. The pro-urokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation.
Behrendt N; List K; Andreasen PA; Danø K
Biochem J; 2003 Apr; 371(Pt 2):277-87. PubMed ID: 12534347
[TBL] [Abstract][Full Text] [Related]
14. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.
Estreicher A; Mühlhauser J; Carpentier JL; Orci L; Vassalli JD
J Cell Biol; 1990 Aug; 111(2):783-92. PubMed ID: 2166055
[TBL] [Abstract][Full Text] [Related]
15. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
16. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
[TBL] [Abstract][Full Text] [Related]
18. Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity.
Ragno P; Montuori N; Vassalli JD; Rossi G
FEBS Lett; 1993 Jun; 323(3):279-84. PubMed ID: 8388810
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
Allan EH; Martin TJ
J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
[TBL] [Abstract][Full Text] [Related]
20. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
